Last updated: July 28, 2026
Executive summary: Dexedrine is an established, mature central nervous system stimulant containing dextroamphetamine, with long-standing FDA commercialization and a large generic/authorized-duplicate footprint. Public clinical-trial and regulatory datasets for “Dexedrine” are not specific enough in this record to support a complete, accurate, drug- and product-level clinical update or a defensible forecast of next-generation entrants, exclusivity loss, or near-term revenue shifts.
What clinical trials have been run for Dexedrine (dextroamphetamine) and what is their status?
Featured snippet answer: No product-specific, up-to-date trial status set for “Dexedrine” can be compiled from the information available here.
Which trial registry entries map to “Dexedrine” versus “dextroamphetamine” broadly?
A compliant clinical update requires a definable mapping from “Dexedrine” to trial titles or protocols that specify the brand product (or at least the exact active substance, dose form, and manufacturer). The present input does not provide that mapping.
What endpoints would matter for a Dexedrine development update?
- ADHD symptom scales and responder definitions
- Wakefulness/attention endpoints (adult vs pediatric stratification)
- Safety endpoints: cardiovascular parameters, insomnia, appetite suppression, abuse potential
- Abuse-deterrent or misuse-resistant endpoints if reformulation is claimed
- Pediatric growth effects and longitudinal follow-up, where applicable
Why are “brand name” updates hard for mature stimulants?
For established stimulants, new studies often use “dextroamphetamine” and enroll irrespective of brand, and registrations may not track manufacturer-level exposure. Without a complete trial list tied to Dexedrine, an update risks being inaccurate.
What patents protect Dexedrine (dextroamphetamine) and how many are still in force?
Featured snippet answer: A complete, accurate patent-coverage count and expiration map cannot be produced from the information available here.
How should patent estate coverage be assessed for Dexedrine?
For a full estate view, an analyst typically pulls:
- Orange Book listed patents by NDA and dosage form
- Expiration dates and patent linkage to each listed formulation/method
- Any use patents, if Orange Book lists them
- Litigation and exclusivity impacts (30-month stays, settlements)
No Orange Book/NDA linkage is provided in this record.
Which patent families usually appear for immediate-release dextroamphetamine products?
- Manufacturing/formulation patents (including polymorph, particle size, excipient systems)
- Method-of-use patents (pediatric indications, dosing regimens)
- Pediatric exclusivity and new clinical data exclusivities (where applicable)
A credible list requires NDA-specific querying.
When does Dexedrine lose exclusivity, and what does that imply for generic entry risk?
Featured snippet answer: A reliable exclusivity timeline cannot be stated from the information available here.
What exclusivity constructs would apply to Dexedrine?
- Patent expiry and patent term adjustments
- Orphan/pediatric exclusivity (if any tied to the relevant NDA)
- Marketing exclusivity for new dosage forms or strengths, if any were granted
- 505(b)(2) pathway exclusivity if a relevant NDA exists for a specific formulation
No NDA-specific exclusivity data is provided.
What generic entry scenarios matter for a mature stimulant?
- Authorized generics and label-compatible reformulations
- Paragraph IV attempts (if any remaining brand exclusivity exists)
- Switch-to-generic dynamics based on payer formularies
What is the Orange Book status of Dexedrine (dextroamphetamine) and which ANDAs are linked?
Featured snippet answer: Orange Book status and ANDA-to-patent linkages cannot be generated from the information available here.
What to extract from Orange Book for a market forecast
- Active listed drug products by NDA
- Listed patents with expiration dates
- ANDA submissions with application numbers and approval status
- Market exclusivity flags
Which companies sell Dexedrine and how does competitive pressure affect pricing and volume?
Featured snippet answer: Dexedrine competes in a category dominated by generics and authorized-duplicate products, but company-level, SKU-level market shares and pricing trajectories cannot be quantified from the information available here.
Commercial structure for dextroamphetamine stimulants
- Multiple manufacturers across immediate-release and extended-release (depending on product)
- Pharmacy benefit manager contracting on net cost rather than list price
- Switching incentives based on continuity of supply and payer restrictions
What levers drive near-term demand for Dexedrine
- Payer step therapy and quantity limits
- Shortages and supply reliability for specific strengths
- Brand-to-generic interchangeability within the same active ingredient class
A projection requires current unit consumption or sales data, which is not present.
How does Dexedrine compare with other dextroamphetamine or amphetamine products in efficacy and market outlook?
Featured snippet answer: A defensible head-to-head market outlook and clinical comparison cannot be completed without specifying the comparator set and sourcing up-to-date utilization and trial outcomes.
Category comparators that analysts typically model
- Mixed amphetamine salts (various IR formulations)
- Lisdexamfetamine (prodrug) products
- Other amphetamine IR brands and long-acting formulations in the US market
Without a defined set and current sales/utilization data, a comparison would be incomplete.
What regulatory pathway updates affect Dexedrine (FDA label changes, REMS, and safety communications)?
Featured snippet answer: No specific FDA label update, safety communication, or regulatory event for “Dexedrine” can be enumerated from the information available here.
What regulatory items would affect commercial planning
- Labeling changes to dosing limits or contraindications
- Pediatric dosing updates and growth monitoring language
- Abuse and dependence warnings updates
- Any Risk Evaluation and Mitigation Strategy changes (if applicable)
No FDA event history is included in this record.
What formulation and manufacturing patent barriers exist for Dexedrine generics and reformulations?
Featured snippet answer: Patent barriers cannot be specified without NDA-level listed patents and their claims.
What barriers typically matter for stimulant generics
- Bioequivalence risk due to formulation variables (release profile for IR products)
- Manufacturing controls and impurity specifications
- Packaging and stability specs for dextroamphetamine salts
- Abuse-deterrent requirements if reformulation is marketed as misuse-resistant
A claim chart requires patent data not available here.
Market projection for Dexedrine: What will demand, pricing, and share look like over the next 3–5 years?
Featured snippet answer: A quantifiable projection cannot be produced from the information available here.
Projection model components that are missing in this record
- Current annual sales by dosage form and strength
- Channel mix (retail vs institutional)
- Generic penetration rates and authorized generic share
- Payer rebate dynamics and net pricing indices
- Competitive launch calendar (extended-release introductions, shortages, supply constraints)
- Regulatory and patent calendar driving entry waves
Without these inputs, any forecast would not be accurate.
Key Takeaways
- Dexedrine is a mature dextroamphetamine stimulant with a market structure dominated by generics and authorized duplicates.
- This input does not include NDA-specific Orange Book, patent-expiration, litigation, trial registry, or current sales/utilization data required to produce a complete clinical-trials update and a defensible 3–5 year market projection.
- A high-integrity update must be grounded in NDA-level regulatory linkages, enumerated patent estates, and contemporaneous sales and trial status records.
FAQs
- How do I find the correct Orange Book entries for “Dexedrine” by NDA and dosage form?
- What’s the difference between clinical trials for “dextroamphetamine” versus the brand “Dexedrine” in registries?
- What data sources drive market projections for established stimulants like dextroamphetamine?
- How do patent expiry and 30-month stays typically affect generic timing for CNS stimulants?
- Which endpoints most often determine adoption of stimulant formulations in pediatrics and adults?
References
No sources were provided in the input, and no external citations can be produced from the available information.
